Comparative Pharmacology
Head-to-head clinical analysis: ALCAINE versus IONTOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAINE versus IONTOCAINE.
ALCAINE vs IONTOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Iontocaine (lidocaine 2% and epinephrine 0.01%) combines a sodium channel blocker (lidocaine) to inhibit nerve impulse propagation, producing local anesthesia, with epinephrine causing vasoconstriction to reduce systemic absorption and prolong effect.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
IONTOCAINE is not a recognized drug. No standard dosing available.
None Documented
None Documented
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Terminal elimination half-life is 2.5-3.0 hours; prolonged in renal impairment (up to 6-8 hours).
Renal excretion of parent drug and metabolites: <5% unchanged.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (15-20%); less than 10% fecal.
Category C
Category C
Local Anesthetic
Local Anesthetic